Can I read Tucatinib, Letrozole, Palbociclib in HR+/HER2+ Cancer on EtoBox?

Tucatinib, Letrozole, Palbociclib in HR+/HER2+ Cancer by Md. Jubaer Hussain is a document available to read on EtoBox.

What is Tucatinib, Letrozole, Palbociclib in HR+/HER2+ Cancer about?

The study evaluates the safety and efficacy of a combination therapy involving tucatinib, letrozole, and palbociclib for patients with HR+/HER2+ metastatic breast cancer. Results from the phase Ib/II trial indicated that the treatment was well tolerated, with a median progression-free survival of 8.4 months and an overall response rate of 44.5%. The findings suggest that this all-oral regimen could be a promising option for patients, warranting further investigation.

Author

Md. Jubaer Hussain

Language

EN